Ziegler Capital Management’s Sage Therapeutics SAGE Stock Holding History

Ziegler Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-12,326	Closed	-$408K	–	407
2022 Q1	$408K	Sell	12,326 -1,060	-8%	-$39.8K	0.02%	340
2021 Q4	$569K	Sell	13,386 -4,672	-26%	-$196K	0.02%	364
2021 Q3	$800K	Buy	18,058 +5,403	+43%	+$248K	0.03%	350
2021 Q2	$719K	Buy	+12,655	New	+$895K	0.02%	364

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Ziegler Capital Management's SAGE Position: Q2 2022 in Review

Ziegler Capital Management sold out of Sage Therapeutics (SAGE) in Q2 2022, closing a stake of 12,326 shares — an estimated $408K sold.

Ziegler Capital Management first reported a position in SAGE in Q2 2021 and held it in 4 quarters. The position peaked at $800K in Q3 2021. 209 funds tracked by Wall St. Rank hold SAGE as of Q2 2022.

Ziegler Capital Management reported no remaining Sage Therapeutics position as of Q2 2022 after selling out during the quarter.
Ziegler Capital Management sold 12,326 Sage Therapeutics shares in Q2 2022, an estimated $408K.
Ziegler Capital Management first reported a position in Sage Therapeutics in Q2 2021 and held it in 4 quarters.
Ziegler Capital Management's Sage Therapeutics position peaked at $800K in Q3 2021.
209 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2022.

Based on Ziegler Capital Management's 13F filing for Q2 2022, filed 21 Jul 2022.